114results about How to "No apparent cytotoxicity" patented technology

The invention relates to a high-toughness corrosion-resistant magnesium alloy implanted material capable of being degraded in an organism, belonging to the technical field of biological materials. The material of the invention comprises the following components in percentage by weight: 1-4% of Nd, 0.1-1.0% of Zn, 0.1-1.0% of Ag, 0.3-0.8% of Zr and balance of Mg. The invention strengthens magnesium alloy through alloy elements, refines grains, improves plasticity, and further strengthens the magnesium alloy through extrusion deformation and heat treatment processes. The corrosion rate of the magnesium alloy provided by the invention in the simulated body fluid is 0.22-0.28mm/year, meeting the requirement of the implanted material for the corrosion rate; and the material of the invention does not have obvious cytotoxicity and has good blood compatibility, thereby meeting the requirements of the implanted material for biological compatibility. The high-plasticity medium-strength magnesium alloy provided by the invention can be used for support intravascular stent materials, and the high-strength medium-plasticity magnesium alloy provided by the invention can be used for implanted materials in orthopaedics.

The invention relates to a tumor-targeted T1-T2 double nuclear magnetic resonance imaging contrast agent and a preparation method and an application thereof. The contrast agent comprises hyaluronic acid-coated ferroferric oxide composite magnetic nanoparticles, wherein the molecular formula of hyaluronic acid is as shown in the specification; n is an integer of 17-290. The preparation method of the contrast agent comprises the following steps: (1) dissolving hyaluronic acid into deionized water, introducing a gas, and heating to obtain a reaction system A; (2) dissolving ferric salt and ferrous salt into a strong acid to obtain a solution B; (3) injecting the solution B into the reaction system A, adjusting the pH to be alkaline, and then refluxing at a high temperature to obtain a reaction system C; and (4) cooling a reaction system C to a room temperature, and dialyzing to obtain the contrast agent. The invention further provides an application of the contrast agent in T1 and T2 weighted imaging in in-vivo and in-vitro nuclear magnetic resonance. The contrast agent provided by the invention has superparamagnetism and outstanding T1 and T2 relaxation enhancement effects, and is suitable for being used as a T1-T2 double nuclear magnetic resonance imaging contrast agent.

The invention provides a nanofiber membrane and a preparation method and application thereof. The nanofiber membrane is formed by fibers of a core-shell structure and is characterized in that the core is formed by mixed fibers mixed by polylactic acid-hydroxyacetic acid and polycaprolactone, the shell is formed by fibers formed by gelatin crosslinking with genipin, and the core is loaded with chemical therapy medicine. The nanofiber membrane prepared by the coaxial electrospinning technology has an in-situ anti-cancer function and is implantable, good in biocompatibility, free of cytotoxicity to normal cells and good in curative effect on tumor. The preparation method is simple, mild in condition, low in cost and easy to popularize and apply.

The invention discloses a fullerene micro-nano material with effects of prevention and/or treatment on myelosuppression and a use thereof. The novel use of the fullerene micro-nano material comprises use of the fullerene and/or metallofullerene micro-nano material in a drug or a drug carrier with at least one of properties such as 1, prevention and/or treatment on myelosuppression, 2, prevention and/or treatment on at least one of myelosuppression-caused leucopenia, platelet decreasing, hemoglobin decreasing and monocyte decreasing, and 3, protection of liver tissue, spleen tissue and kidney tissue. The myelosuppression is caused through tumor radiation therapy or rays producing myelosuppression side effects. The fullerene and/or metallofullerene micro-nano material can prevent and treat myelosuppression and prevent liver, spleen and kidney damage.

The embodiment of the invention provides high-strength-and-toughness and corrosion-resistance magnesium alloy and a preparation method thereof. The alloy solves the problems in the prior art that thedeformation capability of the magnesium alloy is poorer and the plasticity processing is difficult when the magnesium alloy is used for preparing stents, the stents can be uniformly degraded in the body while the ideal supporting effect of alloy is achieved, better corrosion resistant performance is achieved, the corrosion-resistance rate is significantly reduced, and the corrosion is more uniform.

The invention discloses a preparing method for anti-microbial hemostatic chitosan. The preparing method for the anti-microbial hemostatic chitosan comprises the steps that a cationic reagent solution is dropwise added in an epoxy reagent solution, the reaction temperature is controlled at 25-90 DEG C, reaction is conducted for 2-24h, pressure-reduction and distillation are conducted after the reaction is finished, and a quaternary ammonium reagent is obtained; the quaternary ammonium reagent is dissolved in a solvent, and a quaternary ammonium reagent solution is prepared; chitosan is added in an alkaline solution, then the quaternary ammonium reagent solution prepared in the step S1 is added and stirred for reaction, and the anti-microbial chitosan is obtained after washing and drying of raw products. The invention further discloses the application of the anti-microbialhemostatic chitosan. A chitosan anti-microbial hemostatic sponge is prepared, according to the standard of GB/T20944.3-2008, the detected bacteriostasis rate of staphylococcus aureus is greater than or equal to 98%, the bacteriostasis rate of escherichia coli is greater than or equal to 90%, and it is indicated that the prepared chitosan anti-microbial hemostatic sponge has the anti-microbial effect; the hemostatic effect of the prepared anti-microbial hemostatichemostatic sponge is excellent, and hemostatic time is less than or equal to 60 seconds; and the anti-microbial hemostatic sponge prepared by utilizing the chitosan has no obvious cytotoxicity, and biodegradation can be achieved.

The invention relates to the technical field of gene engineering, in particular to novel broad-spectrum chimeric lysin BGS-PlySb and an encoding gene and application thereof. The novel broad-spectrum chimeric lysin BGS-PlySb has an amino acid sequence shown as in SEQ ID NO. 1; the encoding gene of the novel broad-spectrum chimeric lysin BGS-PlySb has a nucleotide sequence shown as in SEQ ID NO. 2. A novel chimeric lysin is constructed by means of gene splicing and is suitable for killing various species of Streptococcus and Staphylococcus, particularly various species of Enterococcus, and Staphylococcus aureus, as well as Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus suis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus mutans, Streptococcus iniae and other species; the novel broad-spectrum chimeric lysin BGS-PlySb has good stability and is insensitive to high-concentration NaCl, recombinant protein GBS-PlySb is well expressible in Escherichia coli BL21 (DE3), and a high dose of GBS-PlySb is free of significant cytotoxicity. Therefore, the novel broad-spectrum chimeric lysin BGS-PlySb is applicable independently to or as an additive to the control of various species of Streptococcus and the treatment of infections caused by these species, and has a promising application prospect.

The invention relates to a preparation method of FGF1 sericin protein gel with activity for promoting cell proliferation and a product thereof. The preparation method comprises the following steps that sericin protein containing human FGF1 protein is extracted by human FGF1 gene modifying silk, and a sericin protein solution containing human FGF1 protein is obtained; after renaturation, an FGF1 sericin protein aqueous solution is obtained after dialysis with water, and FGF1 sericin protein hydrogel is obtained by centrifugation; and the FGF1 sericin protein hydrogel is placed at 4 DEG C, an FGF1 sericin protein gel material is formed by cross-linking of a chemical cross-linking agent or inducement of an inducer. The prepared gel material has the activity of promoting cell proliferation andhas broad application potential in tissue engineering.

The invention relates to healthcare liquor, and specifically relates to rosemary healthcare medicinal liquor. The efficacies of existing qi invigorating, blood nourishing, yin-yang regulating, and viscera tonifying healthcare medicinal liquor are poor, and the healthcare medicinal liquor is not suitable for large-quantity and long-term consumption. With the medicinal liquor provided by the invention, the problems are solved. A manufacturing method of the medicinal liquor comprises steps that: (1) fresh rosemary leaves are washed and are dried by filtering; the leaves are places in a microwaveoven; the leaves are first baked under a high temperature, and then baked under a middle temperature; (2) Mongolian milkvetch root and ligusticum are washed, sliced, and dried; and medlar is washed and dried; (3) the traditional Chinese medicines in the steps (1) and (2) are placed into an alcohol extraction pot, and are soaked by using distillate spirit with an alcoholicity of 50; slag is removed, and a leaching solution is obtained; (4) the leaching solution is placed in a storing pot; distillate spirit with an alcoholicity of 50 is added into the pot; the mixture is stirred and stood, suchthat a mother liquor is obtained; (5) yellow rice wine with an alcoholicity of 24, rock sugar or stevioside, and purified water are added to the mother liquor; the mixture is stirred and stood, such that the rosemary healthcare medicinal liquor is prepared. The rosemary healthcare medicinal liquor provided by the invention has functions of qi invigorating, blood nourishing, yin-yang regulating, viscera tonifying, and the like. The effects are good, and the alcohol content is relatively low, such that the rosemary healthcare medicinal liquor is suitable to be taken for a long time.

The invention provides a reduced sensitive type polymer with the effect of arginine membrane penetration as well as a preparation method of the reduced sensitive type polymer. The polymer can self-assemble in an aqueous medium to form micelle of a shell-core structure; the polymer contains a poly-L-arginine structure, so that the speed that the polymer penetrates through a cell membrane to enter cancer cells is increased; meanwhile, the polymer contains a disulfide bond, so that the polymer can be degraded by relatively high reduction potential energy in cancer cells. The invention further provides application of the reduced sensitive type polymer with the effect of arginine membrane penetration as a drug carrier. After being gathered at tumor tissue through the enhanced permeability and retention effect, the carrier can quickly enter the cancer cells, so that bioavailability and the treatment effect of the drug can be improved.

The invention relates to the technical field of genetic engineering and particularly relates to a streptococcus broad-spectrum chimeric lyase GBS-V12b and a coding gene and application thereof. The streptococcus broad-spectrum chimeric lyase GBS-V12b has an amino acid sequence shown in SEQ ID No. 1. The coding gene of the streptococcus broad-spectrum chimeric lyase GBS-V12b has a nucleotide sequence shown in SEQ ID No. 2. The streptococcus broad-spectrum chimeric lyase GBS-V12b disclosed by the invention can be used for killing a variety of streptococci and staphylococci, particularly streptococcus pneumoniae, streptococcus pyogenes, streptococcus suis, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus mutans, streptococcus iniae, and a variety of enterococci and staphylococcus aureus; the GBS-V12b is good in stability and is insensitive to high-concentration NaCl; the recombinant protein GBS-V12b can be excellently expressed in Escherichia coli BL21 (DE3); high-dosage GBS-V12b is free of obvious cytotoxicity. Therefore, the GBS-V12b can be used for controlling a variety of streptococci and treating infections caused by the streptococci independently or as an additive, thereby having a broad application prospect.

The invention discloses applications of a fullerene structure in preparation of drugs used for treating leukemia. The fullerene structure is taken as an active ingredient, and comprises at least one ingredient selected from an oil soluble fullerene, an oil soluble metal embedded fullerene, a composition of the oil soluble fullerene and the oil soluble metal embedded fullerene, a water soluble fullerene, a water soluble metal embedded fullerene, a composition of the water soluble fullerene and the water soluble metal embedded fullerene, and a pharmaceutical ester or a pharmaceutical salt of theabove six ingredients. The active ingredient is capable of accumulating in bone marrow at a high efficiency; effects are achieved quickly; excellent biocompatibility is achieved; the fullerene structure can be used for preventing and treating leukemia before leukemia model maturation; after leukemia onset, the active ingredient possesses bone marrow part targeted enrichment characteristics, and can be used for rapid prevention, treatment, and repairing of bone marrow haematopoietic function damages by leukemia and other organic damages.

The invention provides magnetic nano pharmaceutical complex and a preparation method application thereof. The magnetic nano pharmaceutical complex comprises ferroferric oxide nanoparticle doped polypyrrole nano-carrier, pharmaceutical DAPT carried on the surface of the polypyrrole nano-carrier, and hyaluronic acid adsorbed to the surface of the polypyrrole nano-carrier that carries the pharmaceutical DAPT. The magnetic nano pharmaceutical complex has high ability to carry the pharmaceutical DAPT, good stability and small particle size, has good penetrating capacity and uniform particle size, has significant magneto-thermal slow control, has long-cycle effect in vivo, has no evident cytotoxicity, has low long-term toxicity and good biocompatibility, has significant killing effect on tumor stem cells, and has better killing effect particularly in connection with magneto-thermal therapy; the preparation method of the complex is simple, has mild conditions and low cost and is easy to popularize and apply.

The invention discloses polysubstituted thieno[2,3-b]pyridine derivatives, and a preparation method and an application thereof. The structural formula of the derivatives are represented by formula I shown in the description. A compound for inhibiting a urea transporter is screened by using an erythrocyte model. Experimental results show that the compounds (represented by formula I-1) can inhibit the permeation of a urea transporter UT-B mediated erythrocyte membrane to urea, and the effect of the compounds has a dose-dependent relationship; the compounds represented by the formula I-1 have nocytotoxic effect on MDCK cells within an effective dose range, so the effect of the compounds represented by the formula I-1 on inhibiting cell permeation urea is irrelevant to the cytotoxicity of thecompounds; the inhibition effect of the compounds represented by the formula I-1 on the urea transporter UT-B is gradually enhanced; the inhibiting effect of the compounds represented by the formulaI-1 on the UT-B is reversible; and in-vivo test results show that the compounds represented by the formula I-1 can significantly increase the urination volume of rats, reduce the concentration of ureain rat urine and reduce the osmotic pressure, so that the compounds represented by the formula I-1 generate a urea selective diuresis effect in vivo.

The invention discloses a hericium erinaceus polysaccharide chelated zinc microcapsule and a preparation method thereof. The method includes utilizing a hericium erinaceus polysaccharide as a raw material, chelating the hericium erinaceus polysaccharide with zinc ions to form a polysaccharide zinc chelate, performing homogenization emulsification and spray drying with carrageenan: chitosan: beta-cyclodextrin as wall materials and performing microencapsulation treatment to obtain the hericium erinaceus polysaccharide chelated zinc microcapsule. The microcapsule overcomes shortcomings of poor antioxidant activity of the traditional hericium erinaceus polysaccharide and low zinc content in the hericium erinaceus polysaccharide chelated zinc (Zn-HEP), can not only improve the dispersibility and the emulsifying dispersibility, but also protect the easily oxidized components in the polysaccharide, enhance stability and antioxidant activity and prolong the shelf life. The prepared hericium erinaceus polysaccharide chelated zinc microcapsule has obvious anti-oxidation activity, and enhances immune function and anti-cancer effect. The preparation method is simple and convenient, capable ofachieving industrial continuous production, and has wide practical value.

The invention relates to the field of water pollution treatment, in particular to application of a microcystin degrading enzyme in degradation of nodularin. The microcystin degrading enzyme is immobilized to L-cysteine-modified graphene oxide material; the steps include (1) activating GO (graphene oxide) with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysulfosuccinimidesodium salt, and modifying the activated GO with L-cysteine to obtain CysGO solution; (2) adding mlrA enzyme liquid into the CysGO solution, mixing well, carrying out shock reaction at 0 DEG C for 60min to obtain immobilized enzyme nano composite CysGO-mlrA solution, filtering the solution with a 0.22 mu m ultrafiltration membrane, washing the obtained solid with water, carrying out suction filtering, and drying to obtain the immobilized enzyme nano composite CysGO-mlrA. It is discovered by the inventor via experiments that the microcystin degrading enzyme can well degrade nodularin; CysGO-mlrA and NOD degraded products have no evident cytotoxicity to lymphocytes in zebrafish.